Selin Kurnaz

Co-founder/CEO of @MassiveBio; Engineer. Making sure that every #cancerpatient gets access to #clinicaltrials. #AI, #oncology, #pharma, #gritforchangingtheworld

[Arturo LoAIza-Bonilla, MD MSEd @DrArturoAI]

Honored to join the @theNCI AI Benchmarks Workshop convened by Dr. Tony Letai, uniting AI & cancer leaders from across the nation. This feels like a modern “summer summit” for AI in cancer care—defining trusted benchmarks to move innovation into real patient impact. #AIinCancer #NCI @mystlukes @MassiveBio @ASCO 🇺🇸 🌎

[Massive Bio @MassiveBio]

A little throwback to ASCO 2026.

Novel immunotherapies, bispecific antibodies, AI diagnostics, four partnership announcements, and conversations that made one thing clear: the future of cancer care is being built right now.

What was your biggest takeaway from ASCO 2026?

#ASCO2026 #Oncology #MassiveBio

[Massive Bio @MassiveBio]

Today, we celebrate the fathers who taught us, raised us, and shaped who we are. At Massive Bio, our work is about giving families more time together, because every milestone with dad matters. Happy Father's Day to the fathers fighting cancer, and to every father supporting a loved one through this journey.

[Massive Bio @MassiveBio]

What does it take to democratize clinical trials?

Our Co-Founder and CEO Selin Kurnaz (@skurnaz) sits down with Abe Sutton (@abesutton), Deputy Administrator and
Director of the CMS Innovation Center, to find out.

Episode 1 of Massively Insightful is live: https://t.co/EXkgyY23tU

#MassivelyInsightful #Oncology #ClinicalTrials #Podcast

[Massive Bio @MassiveBio]

What an incredible two days in Boston.

Massive Bio was proud to sponsor the Digital Health & AI Innovation Summit (DHAI) 2026, and even prouder to have two of our co-founders on stage alongside 130+ global health AI leaders.

Our Co-Founder & Chief Medical AI Officer Arturo LoAIza-Bonilla MD took the Intelligence Revolution Stage on Day 1 to present "AI-Orchestrated Precision Oncology: The Intelligent Patient Journey", making the case for what it truly means to orchestrate AI around the patient, not just the system.

Our Co-Founder and CEO Selin Kurnaz, PhD joined the "Augmented Clinicians, Empowered Patients: The Smart Hospital Revolution" panel, bringing her perspective on how AI can make clinicians more powerful without making patients feel like data points.

We also had the honor of hosting the opening night reception, kicking off the summit with the conversations that matter most.

This is exactly the room Massive Bio belongs in, and we're not done showing up.

#DHAI2026 #DigitalHealth #AIinHealthcare #PrecisionOncology #SmartHospitals #ClinicalTrials

@MassiveBio | @WorldBI_Uk | @DrArturoAI | @skurnaz

[Massive Bio @MassiveBio]

Our Co-Founder and CEO Selin Kurnaz, PhD just wrapped up the @Jefferies Healthcare Investment Conference in New York City, right off the back of ASCO.

At Jefferies, the conversations are different. These are top 20 pharma executives sharing their strategic priorities, their pipelines, their outlook. Our goal is always the same: understand where they're headed, and show them how Massive Bio can be their secret weapon in getting the right therapies to the right patients, faster.

The through-line? The discoveries coming out of American Society of Clinical Oncology (ASCO) need to reach patients. That's exactly what we do.

Next stop: Boston. We're proud to be a sponsor at the Digital Health & AI Innovation Summit (DHAI), hope to see you there.

#ASCO2026 #Jefferies #Oncology #ClinicalTrials #DigitalHealth #HealthcareInnovation #PrecisionOncology

[Massive Bio @MassiveBio]

Our Co-Founder and CEO Selin Kurnaz is en route from ASCO 2026 to the @Jefferies Healthcare Investment Conference in New York City, and the momentum from Chicago is following her there.

American Society of Clinical Oncology (ASCO) 2026 was a defining week for Massive Bio. Nearly 200 meetings. Four press releases. Six new product launches. Remarkable traction across our clinical, commercial, and real world data business lines, and meaningful engagement with every layer of the oncology ecosystem: FDA, NCI, pharmaceutical companies, payers, providers, and patients.

This is what strengthening market leadership looks like.

The conference is over but the work continues.

#ASCO26 #Oncology #ClinicalTrials #CancerCare #HealthcareInnovation #JefferiesHealthcare

[Arturo LoAIza-Bonilla, MD MSEd @DrArturoAI]

Congratulations to Dr. Eric Small @ASCOPres for a fantastic #ASCO26 meeting, and hosting a great @ASCO President’s Reception 👏

[Massive Bio @MassiveBio]

Day 3 at #ASCO2026, and the energy at Booth #IH04 has been incredible.

Following yesterday's announcement of the Reticulum Nexus™ product suite, we've had the privilege of connecting with researchers, clinicians, and innovators from across the globe, all united by the same mission: getting the right patients to the right trials, faster.

Tomorrow, June 1st, our Co-Founder & Chief Medical AI Officer, Arturo LoAIza-Bonilla MD (@DrArturoAI), will be presenting at Session S403:

🗓 "Practical Playbook for Artificial Intelligence, Screening, and Remote Oncology in Resource-Constrained Settings" 🕤 9:45 - 10:00 AM CDT

If you're at McCormick Place, stop by Booth #IH04, we'd love to connect.

#ASCO26 #PrecisionOncology #ClinicalTrials #AI #Oncology

[Massive Bio @MassiveBio]

We're expanding access to oncology clinical trials for underserved communities, with privacy built in from the start.

Massive Bio has deployed its AI-powered pre-screening capabilities through BeeKeeperAI's EscrowAI® platform, leveraging federated confidential computing to match cancer patients to clinical trials without ever moving their sensitive data outside the healthcare provider's environment.

The program initially focuses on the #Atlanta, #Georgia region, working to reach historically underrepresented patient populations who may otherwise never learn about trials they qualify for.

This is what equitable, scalable clinical research looks like: AI traveling to the data, not the other way around.

🔗 Read the full announcement: https://t.co/70DIrGqNSm

[Massive Bio @MassiveBio]

Today, May 20, is International Clinical Trials Day.

Clinical trials are how medicine moves forward. But for too long, finding the right trial has been one of the hardest parts of a cancer diagnosis.

At Massive Bio, we exist to change that. Our AI has matched over 190,000 patients to clinical trials across 17 countries, so that geography, complexity, and time never stand between a patient and a potentially life-changing option.

Every match matters. Every trial matters. Every patient matters.

#InternationalClinicalTrialsDay #ClinicalTrials #OncologyInnovation #CancerCare

[Massive Bio @MassiveBio]

Our Co-Founder and CEO Selin Kurnaz, PhD was in #Nashville for the AGC Partners HCIT & Life Sciences Technology Summit, with 16 investor meetings in a single day.

The investment landscape for healthcare AI is shifting. Traditional software models are being re-evaluated, consolidation is on the horizon, and the platforms that own a vertical with direct patient-consented data at their core are the ones positioned to lead.

Massive Bio is at the center of that shift.

Hear Selin's take on what investors are signaling and what it means for the road ahead, and visit https://t.co/dpOy6AtxAK to see what Massive Bio is bringing to #ASCO2026 and schedule a meeting.

#HealthcareAI #Oncology #ClinicalTrials #HealthTech #PrecisionOncology #ASCO2026 #ASCO26

[Massive Bio @MassiveBio]

Massive Bio and Just Worldwide are partnering to connect more cancer patients to clinical trial opportunities — through patient communities, advocacy groups, and AI-driven trial matching.

Only 3–5% of cancer patients ever enroll in a clinical trial. The barrier is rarely eligibility. It is awareness, access, and trust. Just Worldwide brings deep engagement with patient communities — including underrepresented populations — at a scale that traditional recruitment methods cannot reach. Massive Bio brings the AI infrastructure to match those patients to the right trials at the right moment.

Together, we are closing the gap between patients who qualify and trials that need them.

"As oncologists, we know that the right clinical trial can be a turning point for a patient — but only if they know it exists. Just Worldwide's ability to engage patients and advocacy communities at scale, combined with Massive Bio's AI matching engine, creates a system where the right information finds the right patient at exactly the right moment in their journey."

— Arturo Loaiza-Bonilla, MD, Co-Founder & Chief Medical AI Officer, Massive Bio

🔗 https://t.co/n0ubE6wBYv

@MassiveBio @JWWMedResearch @DrArturoAI

#ClinicalTrials #Oncology #AIinOncology #CancerCare #PatientAccess #HealthEquity #PrecisionOncology

[Massive Bio @MassiveBio]

Massive Bio was featured in Genetic Engineering & Biotechnology News (@GENbio) as part of a deep dive into how AI is reshaping drug discovery and clinical research.

The piece covers a broader shift: big tech is building AI platforms purpose-built for scientific workflows. The inference inflection has arrived in biopharma.

For us, this reinforces what we've been building, AI-driven infrastructure that matches cancer patients to clinical trials with the speed and rigor oncology demands.

🔗: https://t.co/YT6WF0sOCY

[Massive Bio @MassiveBio]

Our Co-Founder & Chief Medical AI Officer Dr. Arturo LoAIza-Bonilla MD (@DrArturoAI) joins leading voices in #hematologic #oncology in this Society of Hematologic Oncology (SOHO) Insider piece on a critical challenge: gaps in patient representation can make even strong trial results harder to apply broadly.

It's a conversation the field needs to keep having.

🔗 https://t.co/KnvG3BB2T8

#ClinicalTrials #Oncology #PatientAccess

[Arturo LoAIza-Bonilla, MD MSEd @DrArturoAI]

@StuartBlitz Sorry, it was just acquired

[Massive Bio @MassiveBio]

@MassiveBio is collaborating with @OpenAI to expand global access to clinical trials. 🌍

Through our collaboration with @OpenAI, we're enabling real-time trial parameterization and free pre-screening services in high-population regions, ensuring that life-changing opportunities are available to patients everywhere, not just those near major research centers.

This is what AI-driven precision oncology looks like in practice: breaking down the barriers that have long kept underserved patients from accessing the trials that could change their lives.

Read the full announcement → https://t.co/IDKxzKgxUw

#ClinicalTrials #AIinHealthcare #PrecisionOncology #HealthEquity #CancerResearch #OpenAI #DigitalHealth

[Arturo LoAIza-Bonilla, MD MSEd @DrArturoAI]

We just announced a collaboration with @OpenAI to make clinical trials computable.
Complex eligibility criteria → structured, machine-readable parameters → real-time patient pre-screening at scale.
Weeks → seconds.
Trials shouldn’t be something patients have to find. Trials should find them.
🔗 https://t.co/CYmpTGjRwO?

[Massive Bio @MassiveBio]

The gap between cancer patients and clinical trials has always been an access problem.

On April 28, we are announcing a collaboration that changes this at a scale never seen before.

Can you guess who we are collaborating with? 👇

#ClinicalTrials #HealthcareAI #Oncology #DigitalHealth #PatientAccess

[Massive Bio @MassiveBio]

We brought together pioneers, survivors, and innovators in Dallas with one shared belief: every cancer patient deserves access to the right clinical trial.

The full Massively Insightful Summit recordings are live.
Every panel. Every speaker. Every moment.

🎥 Watch: https://t.co/0cWilprT51

#oncology #clinicaltrials #cancer